Has Yael Harris, MD received payments from drug or device companies?

Yes. Drug and device makers reported $265 in general payments to Yael Harris, MD across 3 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yael Harris, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yael Harris, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yael Harris, MD

Endocrinology, Diabetes & Metabolism · Great Neck, NYNPI 1164663357

Payments from drug & device makers

What this record shows

This record is dominated by education: $265 of the $265 with a category attached, or 100.0%. Abbott accounts for 75.6% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $200 and has fallen 83.9% since, to $32 in 2023. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NY, where the typical reported total is $1,058.

$265in general payments, 2019–2025

Across 3 payments — averaging $88.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$200
Novo Nordisk$65

$37,609in research payments, 2019–2025

Across 19 payments — averaging $1979.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$38K

What the payments were for

Education$265100%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	1	$200
Novo Nordisk	2	$65

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FreeStyle Lite system$200

How this compares

$265 in reported general payments places this provider in the 30th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024

$245,927

Medicare patients

253

Services billed

9,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	175	$288,766
MounjaroTirzepatide	121	$177,022
JardianceEmpagliflozin	83	$124,783
TrulicityDulaglutide	67	$108,201
FarxigaDapagliflozin Propanediol	48	$58,091
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	25	$49,701
Tresiba Flextouch U-200Insulin Degludec	15	$38,603
ProliaDenosumab	22	$37,613
JanuviaSitagliptin Phosphate	16	$26,266
Lyumjev Kwikpen U-100Insulin Lispro-Aabc	13	$19,835
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	39	$18,131
Metformin Er GastricMetformin Hcl	20	$14,908
Novolog FlexpenInsulin Aspart	37	$13,265
TradjentaLinagliptin	11	$12,495
Tresiba Flextouch U-100Insulin Degludec	13	$11,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Novolog	$65	$292,915188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

Other endocrinology, diabetes & metabolism in Great Neck

Robert BuschAlbany$2.7M
Michael ShanikSmithtown$1.2M
Ajay ChaudhuriBuffalo$888K
Vinay KapoorManhasset$820K
John BilezikianNew York$809K
Barbara HirschManhasset$746K
Martin GrajowerBronx$713K
Anastasios ManessisNew York$656K
Jonas LeibowitzYonkers$613K
Philip OtterbeckStaten Island$575K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →